Skip to content
r2g-neuronal-mitohealth-banner

READY-2-GO
NEURONAL MITOCHONDRIAL HEALTH
ASSAY SERVICE

Predefined assay that provides measurements of mitochondrial location and function in human, iPSC-derived neurons.
THE CHALLENGE

BIOLOGICALLY RELEVANT, NEURONAL, IN VITRO MODELS 

Mitochondrial dysfunction is a hallmark of many neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and dementia. As mitochondrial malfunction is increasingly implicated in the onset of neuronal dysfunction/death, efforts in developing drugs that can mitigate these effects are expanding. Evaluating the effects of any new therapeutic candidate on mitochondrial health is intimately linked to understanding its impacts on the broader, cell-health continuum – information that is indispensable to moving drugs into the clinic. While these assays can be straightforward to establish, most in vitro models use immortalized cell lines, which greatly limits the physiological relevance of the data. 

OUR SOLUTION

USE HUMAN, iPSC-DERIVED GLUTAMATERGIC NEURONS TO ASSESS CHANGES IN NEURONAL MITOCHONDRIAL HEALTH

Our Ready-2-Go Neuronal Mitochondrial Health Assay Service assesses changes in mitochondrial membrane potential that result from treatment with your drug candidates in a physiologically relevant model – human, iPSC-derived glutamatergic neurons. Using high-content microscopy, our assay multiplexes mitochondrial dyes to afford data about the quantity, location, and functional health of mitochondria in the neurons as a whole and separately in the soma and neurites. Combining this with our Ready-2-Go Neurotoxicity Assay Service provides you with a general framework for evaluating the safety of your drug candidates that can save you time and money in your drug-development campaign. 

APPLICABLE RESEARCH & DISEASE AREAS

This assay is valuable in the development of any CNS-targeting therapies. It is highly relevant to any neurodegenerative-disease research, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and frontotemporal dementia.

cp-lines-section-break

ASSAY OUTLINE

Human iPSC-derived glutamatergic neurons (Fujifilm CDI) are seeded and cultured in 384-well plates for 7 days. They are then treated with known mitochondrial stressors (rotenone, oligomycin A, and FCCP) along with your test articles for 4 and 24 hours, at which points the neurons are fixed and stained. Cells are then imaged on a high-content microscope, and images are analyzed to provide you quantitative assessments of your compounds’ effects on mitochondrial function not only in the entire cell, but also separately in the soma and neurites.

r2g-workflow-v3

Slide18-edit

 

Slide19-edit

 

Slide20-edit

 

Slide21-edit

 

Slide22-edit

 

Slide23-edit

 

RELATED READY-2-GO SERVICES

Browse related Ready-2-Go assay offerings. For custom assays, check out our Bespoke Services.

neurotoxicity-icon

R2G NEUROTOXICITY

Multiplexed readouts of viability and apoptosis.
Learn more

neuronal-outgrowth-network-icon

R2G NEURITE OUTGROWTH & NEURITE NETWORK DYNAMICS

Quantification of neurite outgrowth and changes in established neurite networks using human, iPSC-derived neurons.
Learn more

microglia-phagocytosis-icon

R2G MICROGLIA PHAGOCYTOSIS

Measure uptake of a fluorescent bacterial bioparticle by human, iPSC-derived microglia.
Learn more

bespoke-services-banner-neuro

LEARN MORE ABOUT
BESPOKE ASSAY SERVICES

RELATED RESOURCES

PhenoVista_6341_v2-1-1024x683

TITLE

Lorem ipsum

Read more

PhenoVista_6341_v2-1-1024x683

TITLE

Lorem ipsum

Read more

PhenoVista_6341_v2-1-1024x683

TITLE

Lorem ipsum

Read more

CONTACT US

Let's discuss how we can help with your research.